WWC
BMRN icon

Waypoint Wealth Counsel’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waypoint Wealth Counsel’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,002
Closed -$339K – 165
2026
Q1 		$339K Sell
6,002
-1,644
-22% -$95.9K 0.18% 121
2025
Q4 		$454K Sell
7,646
-1,126
-13% -$61.3K 0.17% 121
2025
Q3 		$475K Buy
8,772
+4,417
+101% +$253K 0.19% 100
2025
Q2 		$239K Buy
+4,355
New +$256K 0.12% 153

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Waypoint Wealth Counsel's BMRN Position: Q2 2026 in Review

Waypoint Wealth Counsel sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 6,002 shares — an estimated $339K sold.

Waypoint Wealth Counsel first reported a position in BMRN in Q2 2025 and held it in 4 quarters. The position peaked at $475K in Q3 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Waypoint Wealth Counsel reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Waypoint Wealth Counsel sold 6,002 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $339K.
  • Waypoint Wealth Counsel first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Waypoint Wealth Counsel's BioMarin Pharmaceuticals position peaked at $475K in Q3 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q2 2026, filed 4 Aug 2026.